.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and total survival, leading to FDA approval as well as a brand-new treatment option for people.